Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Impact · against what's priced in

Liquidia sees a positive catalyst as the global settlement resolves the legal overhang that the market had previously refused to price in. United Therapeutics removes a primary source of litigation uncertainty, providing a neutral-to-positive stability shift.

LQDA+0.60

Challenges what's priced in

The price assumes